Millions of asymptomatic women undergo breast screening annually because their doctors tell them to do so. Not only are these women’s presumably healthy breasts being exposed to highly carcinogenic x-rays, but thousands have received a diagnosis of ‘breast cancer’ for entirely benign lesions that when left untreated would have caused no harm to them whatsoever.
New Study: 80% of early-stage breast cancers do not progress to more concerning forms (invasive breast cancer) even after 20 years.
A new study published in the International Journal of Cancer titled, “Is carcinoma in situ a precursor lesion of invasive breast cancer?,” is bringing much needed attention to a long standing cancer myth that is harming tens of thousands of women each year: that in situ (non- or slow-growing) breast lesions (carcinoma) inevitably progress to malignant cancers that will cause harm or death if left untreated through conventional methods. This is simply not true.
The 25-year prospective follow-up study measured the probability of development of invasive breast cancer (BC) following the diagnosis of carcinomas in situ (CIS) by linking the Canadian National Breast Screening Study (CNBSS) to cancer registries and a national vital statistics database. CIS was classified into ductal (DCIS) and lobular carcinoma in situ (LCIS).
The study found that while the average time from the diagnosis of CIS to invasive BC was 6.3 years (±5.6), and the 20-year cumulative incidence probabilities for DCIS and LCIS were 19.0% (95%CI: 11.2, 26.8) and 21.3% (95%CI: 7.1, 35.4) respectively, at 20-year post CIS diagnosis, more than 80% of them remained free of invasive BC.
Clearly, the notion that DCIS and LCIS always progress to invasive cancer, and therefore must be treated aggressively with the present-day ‘standard of care’ — lumpectomy, mastectomy, radiation, and chemotherapy — is disproved. In other words, the natural history of in situ lesions like DCIS – commonly misidentified by conventional oncologists as ‘cancers’ – indicate they progress to invasive breast cancer only 20% of the time, even after 20 years without treatment.
The study concluded:
“This low probability of developing invasive BC post CIS diagnosis does not support the notion that CIS of the breast is an obligate precursor lesion of invasive BC.”
Even ‘Invasive Breast Cancer’ Is Misunderstood
The misunderstanding about in situ breast lesions extends to so-called ‘invasive breast cancer’ (BC) as well. Whereas invasive BC is considered by the conventional medical establishment as a lethal disease process that must be cut, burned or poisoned out of the body as soon as it is found, there is great heterogeneity within this biological category, including forms with very low (indolent) and high risk for progression and death, and the whole gamut types between. Also, several years ago, the journal Lancet Oncology found that some clinically verified “invasive” cancers appear to regress with time if left untreated, further complicating matters:
“Because the cumulative incidence among controls did not reach that of the screened group, we believe that many invasive breast cancers detected by repeated mammography screening do not persist to be detected by screening at the end of 6 years, suggesting that the natural course of many of the screen-detected invasive breast cancers is to spontaneously regress.” [fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][emphasis added]
The present inability of the conventional medical system to identify any clear method to determine the difference between a benign, malignant, or possibly regression-prone form of BC, puts the patient at profound risk of overdiagnosis and overtreatment, the consequences of which can be devastating. The lack of individualized treatment and informed choice leads many women to undergo treatment who may have never experienced disease progression had they chosen to employ watchful waiting, or alternative approaches.
The Larger Issue: ‘Cancer’ Has Been Completely Misunderstood To The Detriment of Millions
A 2013 study published in JAMA titled, “Overdiagnosis and Overtreatment in Cancer: An Opportunity for Improvement,”[1] explains that the word cancer is highly misunderstood and misused. It has become clear that after 30 years of cancer screening with an emphasis on ‘detecting cancer early,’ the goals of such campaigns to reduce the rate of late-stage disease and decrease cancer mortality has clearly not been realized. [See video for an in-depth explanation.] This would not happen if the exponential increase of diagnoses and treatment for ‘early stage’ cancer produced as a result of mammography screening over the past 25 years were actually finding ‘cancers,’ and not so-called indolent lesions of epithelial origin – i.e. benign lesions that will not progress to malignancy.
The new study expanded on these implications:
“What has emerged has been an appreciation of the complexity of the pathologic condition called cancer. The word “cancer” often invokes the specter of an inexorably lethal process; however, cancers are heterogeneous and can follow multiple paths, not all of which progress to metastases and death, and include indolent disease that causes no harm during the patient’s lifetime. Better biology alone can explain better outcomes.”
“Use of the term “cancer” should be reserved for describing lesions with a reasonable likelihood of lethal progression if left untreated. There are 2 opportunities for change. First, premalignant conditions (e.g., ductal carcinoma in situ or high-grade prostatic intraepithelial neoplasia) should not be labeled as cancers or neoplasia, nor should the word “cancer” be in the name. Second, molecular diagnostic tools that identify indolent or low-risk lesions need to be adopted and validated. Another step is to reclassify such cancers as IDLE (indolent lesions of epithelial origin) conditions.”
[/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]
